PL1974020T3 - Sposoby uzyskiwania unieśmiertelnionych komórek wydzielających przeciwciała - Google Patents

Sposoby uzyskiwania unieśmiertelnionych komórek wydzielających przeciwciała

Info

Publication number
PL1974020T3
PL1974020T3 PL06830666T PL06830666T PL1974020T3 PL 1974020 T3 PL1974020 T3 PL 1974020T3 PL 06830666 T PL06830666 T PL 06830666T PL 06830666 T PL06830666 T PL 06830666T PL 1974020 T3 PL1974020 T3 PL 1974020T3
Authority
PL
Poland
Prior art keywords
methods
cells
human
secrete
secreting cells
Prior art date
Application number
PL06830666T
Other languages
English (en)
Inventor
Ada Funaro
Gianni Garotta
Marianne Murphy
Original Assignee
Ribovax Biotechnologies Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribovax Biotechnologies Sa filed Critical Ribovax Biotechnologies Sa
Publication of PL1974020T3 publication Critical patent/PL1974020T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL06830666T 2005-12-16 2006-12-15 Sposoby uzyskiwania unieśmiertelnionych komórek wydzielających przeciwciała PL1974020T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2005056871 2005-12-16
EP06830666A EP1974020B1 (en) 2005-12-16 2006-12-15 Methods for obtaining immortalized antibody secreting cells
PCT/EP2006/069780 WO2007068758A1 (en) 2005-12-16 2006-12-15 Methods for obtaining immortalized antibody secreting cells

Publications (1)

Publication Number Publication Date
PL1974020T3 true PL1974020T3 (pl) 2011-11-30

Family

ID=36685876

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06830666T PL1974020T3 (pl) 2005-12-16 2006-12-15 Sposoby uzyskiwania unieśmiertelnionych komórek wydzielających przeciwciała

Country Status (19)

Country Link
US (1) US8338172B2 (pl)
EP (1) EP1974020B1 (pl)
JP (2) JP5431730B2 (pl)
KR (1) KR101508945B1 (pl)
CN (1) CN101374944B (pl)
AT (1) ATE513034T1 (pl)
AU (1) AU2006325236B2 (pl)
BR (1) BRPI0619908A2 (pl)
CA (1) CA2633601C (pl)
DK (1) DK1974020T3 (pl)
EA (1) EA019505B1 (pl)
ES (1) ES2367322T3 (pl)
IL (1) IL192095A0 (pl)
NO (1) NO20083160L (pl)
NZ (1) NZ569816A (pl)
PL (1) PL1974020T3 (pl)
PT (1) PT1974020E (pl)
WO (1) WO2007068758A1 (pl)
ZA (2) ZA200806094B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
US8202518B2 (en) 2007-07-04 2012-06-19 Ribovax Biotechnologies S.A. Antibodies against human cytomegalovirus (HCMV)
EP3293269A1 (en) * 2007-08-03 2018-03-14 MUSC Foundation For Research Development Human monoclonal antibodies and methods for producing the same
EP2190876A1 (en) * 2007-08-22 2010-06-02 Ribovax Biotechnologies SA Antibodies against human cytomegalovirus (hcmv)
PT3009449T (pt) 2008-07-16 2018-09-28 Inst Res Biomedicine Anticorpos neutralizantes de citomegalovírus humano e utilização destes
US8703486B2 (en) 2008-09-23 2014-04-22 UNIVERSITé LAVAL Method for polyclonal immunoglobulin G production by human B cells
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
WO2011062997A2 (en) 2009-11-17 2011-05-26 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
EA201270662A1 (ru) 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
ES2434256T3 (es) * 2010-05-28 2013-12-16 F. Hoffmann-La Roche Ag Método de cultivo de células B individuales y producción de anticuerpos específicos
EP2591000B1 (en) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
CN102839152A (zh) * 2011-06-20 2012-12-26 中国科学院上海生命科学研究院 一种快速高效获得抗原特异性b细胞的方法
WO2013000982A1 (en) 2011-06-27 2013-01-03 Vivalis Method for screening cells
US9757458B2 (en) * 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
EP2797952B1 (en) 2011-12-28 2019-02-27 ImmunoQure AG Method of providing monoclonal auto-antibodies with desired specificity
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
US20140199319A1 (en) * 2012-12-14 2014-07-17 Abbvie, Inc. Methods for increasing the efficiency of hybridoma generation
AU2013372026B2 (en) * 2013-01-03 2018-11-08 Merck Patent Gmbh Method for producing secretable antibodies by expression in saccharomyces cerevisiae
WO2015001047A1 (en) 2013-07-03 2015-01-08 Immunoqure Ag Method of providing anti-human cytokine antibodies for pharmaceutical use
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
JP6916884B2 (ja) * 2017-01-02 2021-08-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ細胞培養法
EP3573649A4 (en) * 2017-01-27 2020-12-30 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. VACCINE COMPOSITIONS OF HERPESVIRUS ENVELOPE PROTEIN COMBINATIONS INTENDED TO INDUCE AN IMMUNE RESPONSE
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN111647566A (zh) * 2019-07-10 2020-09-11 广州医科大学附属第一医院 一种高滴度eb病毒的制备方法、eb病毒永生化记忆性b细胞的方法与应用
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
US20260002127A1 (en) * 2022-12-06 2026-01-01 Kitayama Labes Co., Ltd. Method for producing immortalized cell
CN117230258B (zh) * 2023-11-10 2024-04-09 苏州驾玉生物医药有限公司 一种提高灵敏度的培养扩增联合pcr的eb病毒检测方法
CN119285758B (zh) * 2024-10-31 2025-07-01 上海百英生物科技股份有限公司 一种基于b细胞永生化的单个b细胞抗体开发方法及其应用
CN120272432B (zh) * 2025-03-25 2025-12-26 佛山市妇幼保健院 一种脊髓性肌萎缩症质控品及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
ATE132907T1 (de) * 1989-09-19 1996-01-15 Centocor Inc Verfahren zur verbesserten herstellung von menschlichen antikörpern sowie hierzu benutzte zellen
ATE449853T1 (de) 1990-02-01 2009-12-15 Siemens Healthcare Diagnostics HERSTELLUNG UND VERWENDUNG VON GENBANKEN MENSCHLICHER ANTIKÖRPER(ßHUMAN-ANTIKÖRPER- BIBLIOTHEKENß)
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6399384B1 (en) * 1999-09-17 2002-06-04 Reneuron Limited Conditional immortalization of cells
FR2817875B1 (fr) 2000-12-07 2005-03-18 Technopharm Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation
AU2004215125B2 (en) * 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
GB2398783A (en) * 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
DE602006021324D1 (de) * 2005-08-23 2011-05-26 Iq Corp Verfahren zur herstellung stabiler b-lymphozyten

Also Published As

Publication number Publication date
AU2006325236B2 (en) 2011-11-10
ZA200806094B (en) 2009-06-24
BRPI0619908A2 (pt) 2011-10-25
HK1127783A1 (en) 2009-10-09
ZA200904907B (en) 2010-04-28
CA2633601A1 (en) 2007-06-21
EP1974020B1 (en) 2011-06-15
AU2006325236A1 (en) 2007-06-21
ES2367322T3 (es) 2011-11-02
WO2007068758A1 (en) 2007-06-21
IL192095A0 (en) 2008-12-29
CN101374944B (zh) 2012-02-08
EP1974020A1 (en) 2008-10-01
NO20083160L (no) 2008-09-10
PT1974020E (pt) 2011-08-26
JP2013255515A (ja) 2013-12-26
KR20080097181A (ko) 2008-11-04
US8338172B2 (en) 2012-12-25
KR101508945B1 (ko) 2015-04-08
CN101374944A (zh) 2009-02-25
NZ569816A (en) 2011-10-28
US20090270268A1 (en) 2009-10-29
JP2009519026A (ja) 2009-05-14
ATE513034T1 (de) 2011-07-15
DK1974020T3 (da) 2011-10-03
EA019505B1 (ru) 2014-04-30
EA200870062A1 (ru) 2009-04-28
CA2633601C (en) 2015-06-30
JP5431730B2 (ja) 2014-03-05

Similar Documents

Publication Publication Date Title
IL192095A0 (en) Methods for obtaining immortalized antibody secreting cells
US12351825B2 (en) Soluble antibody complexes for T cell or NK cell activation and expansion
PH12020500160A1 (en) Reagents for expanding cells expressing recombinant receptors
Stemberger et al. Novel serial positive enrichment technology enables clinical multiparameter cell sorting
TW200714711A (en) Anti-cd-20 monoclonal antibody
MY150553A (en) Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
MX2010007729A (es) Vectores de expresion de mamifero mejorados y uso de los mismos.
AU2018338418A1 (en) Anti-HLA-A2 antibodies and methods of using the same
Dang et al. Soluble CD27 induces IgG production through activation of antigen‐primed B cells
TN2010000616A1 (en) Human cytomegalovirus neutralising antibodies and use thereof
MX2021014966A (es) Anticuerpos anti-cd3 dependientes de ph modificados geneticamente y metodos para su generacion y uso.
MX2022013956A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion especificas de cd70.
Ukena et al. Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity
WO2009035738A3 (en) Use of antibody secreting cell elispot to assess antibody responses following antigen exposure
Correa et al. Evaluation of antigen-conjugated fluorescent beads to identify antigen-specific B cells
WO2011050985A8 (en) Clonal expansion of b cells
Vásquez et al. Rapid proliferation and differentiation of a subset of circulating IgM memory B cells to a CpG/cytokine stimulus in vitro
Liu et al. A rapid method to characterize mouse IgG antibodies and isolate native antigen binding IgG B cell hybridomas
Scholzen et al. Expansion of IgG+ B-cells during mitogen stimulation for memory B-cell ELISpot analysis is influenced by size and composition of the B-cell pool
Barbeau et al. Generation of a human induced pluripotent stem cell line (iPSC) from peripheral blood mononuclear cells of a patient with a myasthenic syndrome due to mutation in COLQ
WO2006089002A3 (en) Method for high throughput screening for antibodies and proteins inducing apoptosis
UA72439U (ru) Тест-система иммуноферментная для качественного и полуколичественного определения антител класса igg к вирусам простого герпеса 2 типа, унифицированная "dia-hsv 2-igg-u"
Manna et al. Autologous crossmatches: How useful are they in the evaluation of positive donor flow cytometric crossmatches?
UA72423U (ru) ИММУНОФЕРМЕНТНАЯ ТЕСТ-СИСТЕМА ДЛЯ КОЛИЧЕСТВЕННОГО АНАЛИЗА И ОПРЕДЕЛЕНИЯ АВИДНОСТИ АНТИТЕЛ КЛАССА IgG ВИРУСА КРАСНУХИ (DIA-RUBELLA-IGG-AV)
RU2016122025A (ru) Клон культивируемых гибридных клеток животного mus musculus l. rv-4 - продуцент моноклональных антител, специфичных к рибонуклеопротеину вируса бешенства (n-белку)